U.S. Markets closed

Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017


Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will release financial results for the fiscal year ended October 31, 2017 on Wednesday, December 20, 2017.

Advaxis’ senior management will host a conference call to review its financial results and provide a business update, which will include a discussion of the advantages of its Lm-based antigen delivery platform and clinical pipeline. The conference call and live audio webcast will begin at 10:00 a.m. Eastern time on Thursday, December 21, 2017.

Conference Call & Webcast Information

WHEN: Thursday, December 21, 2017 at 10:00 a.m. Eastern time.
DOMESTIC DIAL-IN: (844) 348-6133
WEBCAST: www.ir.advaxis.com/news-events

For those unable to participate in the live conference call or webcast, a digital recording will be available beginning December 21, 2017 two hours after the close of the conference call. To access the recording, dial (855) 859-2056 or (404) 537-3406 and provide the operator with the conference ID: 4682169. In addition, the audio webcast will be archived on the Company’s website for a period of time at www.ir.advaxis.com/news-events.

About Advaxis, Inc.

Advaxis, Inc., located in Princeton N.J., is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and pre-clinical development: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

To learn more about Advaxis, visit www.advaxis.com and connect on TwitterLinkedInFacebook, and YouTube.

Advaxis Forward-Looking Statement

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis’ SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at www.sec.gov.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171214005065/en/